RPG Life Sciences Ends Week Slightly Lower Despite Technical Recovery and Mixed Signals
2026-11-21 17:07:09Key Events This Week 16 Nov: Downgrade to Sell amid technical weakness and flat financials 16 Nov: Technical momentum shifts to sideways trend 19 Nov: Upgrade to Hold on technical improvements and stable fundamentals 20 Nov: Week closes at Rs.2,537.25 (-0.56%) Week OpenRs.2,571.35 Week CloseRs....
Read More
RPG Life Sciences Ltd Upgraded to Hold on Technical Improvements and Stable Fundamentals
2026-11-19 08:22:43RPG Life Sciences Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, and financial trends despite flat quarterly results. The pharmaceutical and biotechnology company’s recent performance and market positioning warrant a closer look at the factors driving this change.
Read More
RPG Life Sciences Ltd Faces Technical Momentum Shift Amid Mixed Market Signals
2026-11-16 08:01:43RPG Life Sciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators reveal a complex picture, with some signals pointing to caution while others suggest underlying strength, reflecting the stock’s nuanced market positioning as it trades near ₹2,551.
Read More
RPG Life Sciences Ltd is Rated Sell by MarketsMOJO
2026-11-15 10:10:16RPG Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 November 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 15 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreRPG Life Sciences Declines 0.62% Despite Mixed Technical Signals and Downgrade
2026-11-07 17:07:10Key Events This Week Nov 2: Stock opens at Rs.2,548.10, declines 0.94% amid Sensex rally Nov 3: Further dip to Rs.2,536.30 following downgrade announcement Nov 4: Downgrade to Sell rating announced; technical momentum shifts noted Nov 5: Mildly bullish technical shift lifts price to Rs.2,602.35 (+2.60%) Nov 6: Price retreats to Rs.2,556.55 (-1.05%) closing the week lower Week Open<...
Read More
RPG Life Sciences Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals
2026-11-05 08:02:50RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite this positive directional change, a detailed analysis of key technical indicators such as MACD, RSI, moving averages, and others reveals a complex picture with mixed signals that investors should carefully consider.
Read More
RPG Life Sciences Ltd Faces Technical Momentum Shift Amid Mixed Indicator Signals
2026-11-04 08:02:35RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of indicator signals. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s long-term returns remain robust, though short-term price action signals caution for investors.
Read MoreRPG Life Sciences Ltd’s Volatile Week: -1.75% Amid Margin Pressures and Market Shifts
2026-10-31 17:05:06Key Events This Week Oct 26: Stock surges 5.29% to Rs.2,756.75 on valuation upgrade Oct 27: Continued gains with 2.42% rise to Rs.2,823.50 Oct 29: Sharp 5.21% jump to Rs.2,995.65 amid strong volume Oct 30: Intraday low hit Rs.2,749.55; closes down 14.13% at Rs.2,572.40 Week OpenRs.2,618.15 Week Close<div class="stat-v...
Read More
RPG Life Sciences Ltd Reports Flat Quarterly Performance Amid Margin Pressure
2026-10-30 11:00:13RPG Life Sciences Ltd has reported a flat financial performance for the quarter ended September 2026, marking a notable shift from its previously positive growth trajectory. Despite achieving its highest-ever quarterly net sales of ₹211.64 crores, the company witnessed an 8.8% decline in profit after tax (PAT) compared to the average of the preceding four quarters, signalling margin pressures and a cautious outlook for investors.
Read MoreAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript
05-Nov-2026 | Source : BSEEarning call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
31-Oct-2026 | Source : BSENewspaper publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
30-Oct-2026 | Source : BSEAudio Recording of Q2FY27 Results Earnings Call held on October 30 2026
Corporate Actions
No Upcoming Board Meetings
RPG Life Sciences Ltd has declared 300% dividend, ex-date: 09 Jul 26
No Splits history available
No Bonus history available
No Rights history available